Conclusions
normoalbuminuric CKD, CKD
The main findings of the present analysis are that certain patient subgroups, especially non-albuminuric CKD-patients, a common group in clinical practice, were not included in the finerenone RCTs. Furthermore, the registry data showed an undertreatment of CKD patients with RAS blockers in clinical practice, although guidelines clearly recommend such treatment. These limitations result in the study population being only partially comparable to clinical practice as data on finerenone are, therefore, not available for certain common patient groups. Further research into patients with normoalbuminuric CKD and a wider prescription of RAS blocking agents for patients with CKD in clinical practice appears warranted.